159 related articles for article (PubMed ID: 22223257)
1. In vivo therapeutic effect of CDH3/P-cadherin-targeting radioimmunotherapy.
Yoshioka H; Yamamoto S; Hanaoka H; Iida Y; Paudyal P; Higuchi T; Tominaga H; Oriuchi N; Nakagawa H; Shiba Y; Yoshida K; Osawa R; Katagiri T; Tsunoda T; Nakamura Y; Endo K
Cancer Immunol Immunother; 2012 Aug; 61(8):1211-20. PubMed ID: 22223257
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Characterization of the Radioimmunoconjugate
Funase Y; Nakamura E; Kajita M; Saito Y; Oshikiri S; Kitano M; Tokura M; Hino A; Uehara T
J Nucl Med; 2021 Feb; 62(2):232-239. PubMed ID: 32737245
[TBL] [Abstract][Full Text] [Related]
3. Fractionated radioimmunotherapy with ⁹⁰Y-labeled fully human anti-CEA antibody.
Hanaoka H; Kuroki M; Yamaguchi A; Achmad A; Iida Y; Higuchi T; Oriuchi N; Tsushima Y; Endo K
Cancer Biother Radiopharm; 2014 Mar; 29(2):70-6. PubMed ID: 24299067
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.
Yudistiro R; Hanaoka H; Katsumata N; Yamaguchi A; Tsushima Y
Mol Pharm; 2018 Jun; 15(6):2165-2173. PubMed ID: 29733658
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy evaluation of radioimmunotherapy with
Sudo H; Tsuji AB; Sugyo A; Saga T; Kaneko MK; Kato Y; Higashi T
Cancer Sci; 2019 May; 110(5):1653-1664. PubMed ID: 30801908
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer.
Yoshida C; Tsuji AB; Sudo H; Sugyo A; Kikuchi T; Koizumi M; Arano Y; Saga T
PLoS One; 2013; 8(3):e59248. PubMed ID: 23516616
[TBL] [Abstract][Full Text] [Related]
7. CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with 111In and 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer.
Watanabe N; Oriuchi N; Endo K; Inoue T; Kuroki M; Matsuoka Y; Tanada S; Murata H; Kim EE; Sasaki Y
J Nucl Med; 2000 Feb; 41(2):337-44. PubMed ID: 10688120
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study of P-cadherin-targeted Radioimmunotherapy with
Subbiah V; Erwin W; Mawlawi O; McCoy A; Wages D; Wheeler C; Gonzalez-Lepera C; Liu H; Macapinlac H; Meric-Bernstam F; Hong DS; Pant S; Le D; Santos E; Gonzalez J; Roszik J; Suzuki T; Subach RA; Madden T; Johansen M; Nomura F; Satoh H; Matsuura T; Kajita M; Nakamura E; Funase Y; Matsushima S; Ravizzini G
Clin Cancer Res; 2020 Nov; 26(22):5830-5842. PubMed ID: 32816889
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.
Liu Z; Liu Y; Jia B; Zhao H; Jin X; Li F; Chen X; Wang F
Mol Cancer Ther; 2010 Aug; 9(8):2297-308. PubMed ID: 20682654
[TBL] [Abstract][Full Text] [Related]
11. Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers.
Garambois V; Glaussel F; Foulquier E; Ychou M; Pugnière M; Luo RX; Bezabeh B; Pèlegrin A
BMC Cancer; 2004 Oct; 4():75. PubMed ID: 15488142
[TBL] [Abstract][Full Text] [Related]
12. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
13. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment of pancreatic cancer xenograft with
Aung W; Tsuji AB; Sudo H; Sugyo A; Ukai Y; Kouda K; Kurosawa Y; Furukawa T; Saga T; Higashi T
World J Gastroenterol; 2017 Nov; 23(42):7551-7562. PubMed ID: 29204055
[TBL] [Abstract][Full Text] [Related]
17. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
[TBL] [Abstract][Full Text] [Related]
18. 166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188Re radiolabel.
Thompson S; Ballard B; Jiang Z; Revskaya E; Sisay N; Miller WH; Cutler CS; Dadachova E; Francesconi LC
Nucl Med Biol; 2014 Mar; 41(3):276-81. PubMed ID: 24533987
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
20. 90Y-Labeled Anti-ROBO1 Monoclonal Antibody Exhibits Antitumor Activity against Small Cell Lung Cancer Xenografts.
Fujiwara K; Koyama K; Suga K; Ikemura M; Saito Y; Hino A; Iwanari H; Kusano-Arai O; Mitsui K; Kasahara H; Fukayama M; Kodama T; Hamakubo T; Momose T
PLoS One; 2015; 10(5):e0125468. PubMed ID: 26017283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
